Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination

Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil
Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil
Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brazil
Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brazil/ Fundação Hospitalar do Estado de Minas Gerais. Hospital Eduardo de Menezes. Belo Horizonte, MG, Brazil
Fundação Hospitalar do Estado de Minas Gerais. Hospital Eduardo de Menezes. Belo Horizonte, MG, Brazil Ana Carolina Campi Azevedo
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil
Empresa Brasileira de Serviços Hospitalares. Universidade Federal do Espírito Santo. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil
Fundação Oswaldo Cruz. Biomanguinhos. Rio de Janeiro, RJ, Brazil
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil
Secretaria de Estado de Saúde de Minas Gerais. Belo Horizonte, MG, Brazil/Ministério da Saúde. Secretaria de Vigilância em Saúde Departamento de Vigilância das Doenças Transmissíveis. Brasília, DF, Brazil
Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil
Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brazil

Resumen en ingles

The yellow fever (YF) vaccine consists of an attenuated virus, and despite its relative safety, some adverse events following YF vaccination have been described. At the end of 2016, Brazil experienced the most massive sylvatic yellow fever outbreak over the last 70 years and an intense campaign of YF vaccination occurred in Minas Gerais state in Southeast Brazil from 2016 to 2018. The present study aimed to develop a genotyping tool and investigate 21 cases of suspected adverse events following YF vaccination. Initial in silico analyses were performed using partial NS5 nucleotide sequences to verify the discriminatory potential between wild-type and vaccine viruses. Samples from patients were screened for the presence of the YFV RNA, using 50UTR as the target, and then used for amplification of partial NS5 gene amplification, sequencing, and phylogenetic analysis. Genotyping indicated that 17 suspected cases were infected by the wild-type yellow fever virus, but four cases remained inconclusive. The genotyping tool was e_cient in distinguishing the vaccine from wild-type virus, and it has the potential to be used for the di_erentiation of all yellow fever virus genotypes.

Palabras clave en ingles

yellow fever virus
YFV-17DD
adverse event
arbovirus
yellow fever
vaccination
immunisation
vaccine
genotyping
wild-type virus

Editor

MDPI AG

Referencia

REZENDE, Izabela Maurício et al. Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination. Vaccines, v. 7, n. 4, 206, 2019

DOI

10.3390/vaccines7040206

ISSN

2076-393X

Por favor, use este identificador para citar o enlazar este ítem: https://www.arca.fiocruz.br/handle/icict/41493

Tipo

Derechos de autor

Acceso abierto

Objetivos de Desarrollo Sostenible

Colecciones

Compartir

Estadísticas

Metadatos

Autor

Afiliación